The FDA, Marathon Pharmaceuticals, and Biogen are leading the pre- and post-approval strategy and integrated medical launches for Multiple Sclerosis (MS).
1 report, 1 independent
Updated Sep 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA, Marathon Pharmaceuticals, and Biogen are leading the pre- and post-approval strategy and integrated medical launches for Multiple Sclerosis (MS).
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Marathon Pharmaceuticals
former U.S. rare disease drug company
Nothing else this week.
-
Biogen
American multinational biotechnology company
Nothing else this week.
Related events
- Generic medicine services are seeking approval for launch from the FDA.
- EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- BioTech generated encouraging early data for MASH and POTS, and expects an FDA decision regarding cemdisiran next month.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.